H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Aclaris Therapeutics to $43 from $50 and keeps a Buy rating on the shares. The analyst says the mid-stage data in hidradenitis suppurativa disappointed.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ACRS:
- Aclaris Plummets after Zunsemetinib Data Disappoints
- Aclaris Therapeutics announces preliminary data from Phase 2 study of ATI-450
- Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
- Aclaris Therapeutics reports Q4 EPS (41c), consensus (45c)
- Stifel biotechnology analyst to hold an analyst/industry conference call